OA11842A - Method for treating COPD. - Google Patents

Method for treating COPD. Download PDF

Info

Publication number
OA11842A
OA11842A OA1200100226A OA1200100226A OA11842A OA 11842 A OA11842 A OA 11842A OA 1200100226 A OA1200100226 A OA 1200100226A OA 1200100226 A OA1200100226 A OA 1200100226A OA 11842 A OA11842 A OA 11842A
Authority
OA
OAPI
Prior art keywords
rolipram
pde
ic5q
binds
ratio
Prior art date
Application number
OA1200100226A
Other languages
English (en)
Inventor
Siegfried B Christensen
Mary S Barnette
Theodore J Torphy
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of OA11842A publication Critical patent/OA11842A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200100226A 1999-03-01 2000-03-01 Method for treating COPD. OA11842A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12231599P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
OA11842A true OA11842A (en) 2005-08-22

Family

ID=22401990

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100226A OA11842A (en) 1999-03-01 2000-03-01 Method for treating COPD.

Country Status (30)

Country Link
US (1) US6670394B1 (sk)
EP (1) EP1156799A4 (sk)
JP (1) JP2002538114A (sk)
KR (1) KR20010102459A (sk)
CN (1) CN1349403A (sk)
AP (1) AP2001002248A0 (sk)
AR (1) AR042369A1 (sk)
AU (1) AU772583B2 (sk)
BG (1) BG105953A (sk)
BR (1) BR0008603A (sk)
CA (1) CA2366036A1 (sk)
CO (1) CO5160248A1 (sk)
CZ (1) CZ20013149A3 (sk)
DZ (1) DZ3019A1 (sk)
EA (1) EA200100930A1 (sk)
HK (1) HK1043935A1 (sk)
HU (1) HUP0200288A3 (sk)
ID (1) ID29888A (sk)
IL (1) IL144992A0 (sk)
MA (1) MA25522A1 (sk)
NO (1) NO20014222L (sk)
NZ (1) NZ513695A (sk)
OA (1) OA11842A (sk)
PE (1) PE20001505A1 (sk)
PL (1) PL352816A1 (sk)
SK (1) SK12372001A3 (sk)
TR (1) TR200102514T2 (sk)
UY (1) UY26040A1 (sk)
WO (1) WO2000051598A1 (sk)
ZA (1) ZA200107186B (sk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
CA2503290C (en) 2003-03-10 2012-12-04 Altana Pharma Ag Novel process for the preparation of roflumilast
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
JPWO2005056009A1 (ja) * 2003-12-12 2007-07-05 協和醗酵工業株式会社 肺疾患治療剤
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
CA2601250C (en) 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633776B1 (en) * 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1993019751A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
SI0710109T1 (en) 1993-06-18 2005-02-28 Smithkline Beecham Corporation Method for identifying a PDE IV inhibitor
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
EP0730588B1 (en) * 1993-11-26 1997-07-02 Pfizer Inc. Isoxazoline compounds as antiinflammatory agents
UY25338A1 (es) 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd

Also Published As

Publication number Publication date
MA25522A1 (fr) 2002-10-01
NZ513695A (en) 2001-09-28
WO2000051598A1 (en) 2000-09-08
EA200100930A1 (ru) 2002-02-28
PE20001505A1 (es) 2001-02-08
UY26040A1 (es) 2000-09-29
HK1043935A1 (zh) 2002-10-04
ID29888A (id) 2001-10-18
BG105953A (en) 2002-05-31
JP2002538114A (ja) 2002-11-12
KR20010102459A (ko) 2001-11-15
TR200102514T2 (tr) 2002-04-22
BR0008603A (pt) 2001-12-26
AP2001002248A0 (en) 2001-09-30
AU3386900A (en) 2000-09-21
PL352816A1 (en) 2003-09-08
CA2366036A1 (en) 2000-09-08
HUP0200288A3 (en) 2003-08-28
US6670394B1 (en) 2003-12-30
HUP0200288A2 (hu) 2002-05-29
SK12372001A3 (sk) 2001-12-03
EP1156799A4 (en) 2004-11-10
EP1156799A1 (en) 2001-11-28
CO5160248A1 (es) 2002-05-30
IL144992A0 (en) 2002-06-30
AU772583B2 (en) 2004-04-29
AR042369A1 (es) 2005-06-22
DZ3019A1 (fr) 2005-05-20
NO20014222L (no) 2001-10-29
NO20014222D0 (no) 2001-08-31
ZA200107186B (en) 2002-08-30
CZ20013149A3 (cs) 2002-04-17
CN1349403A (zh) 2002-05-15

Similar Documents

Publication Publication Date Title
US5998428A (en) Compounds and methods for treating PDE IV-related diseases
US6555576B1 (en) Method for treating exercise induced asthma
Gawin et al. Desipramine facilitation of initial cocaine abstinence
OA11842A (en) Method for treating COPD.
EP0710109B1 (en) Method for identifying a PDE IV inhibitor
UA97101C2 (uk) Фармацевтичні комбінації, які містять тестостерон, для лікування жіночої сексуальної дисфункції
Kinross-Wright Chlorpromazine treatment of mental disorders
Nademanee Cardiovascular effects and toxicities of cocaine
US20060019963A1 (en) Compounds
Cartledge et al. Sildenafil
JPH05506441A (ja) 加齢関連記憶障害およびその他の認識障害の治療のための化合物
MXPA01008853A (en) Method for treating copd
US20020115111A1 (en) Compounds
ZA200107187B (en) Method for treating exercise induced asthma.
Bousquet Rapid symptom relief in rhinitis
Gessner et al. The disulfiram-ethanol reaction
MXPA01008858A (en) Method for treating exercise induced asthma
Schwartz The long QT syndrome: a clinical counterpart of hERG mutations
HARRINGTON et al. The interrelationships of alcohol dehydrogenase and the aldehyde dehydrogenases in the metabolism of ethanol in liver
Taylor Central nervous system stimulants
Dukes Antihistamines
Kalman Blood levels of drugs used in the treatment of cardiac arrhythmias
Yeung Laiwah Studies on the acute hepatic porphyrias